Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients

Status:
Terminated

Trial end date:
2021-03-31

Target enrollment:

Participant gender:

Unresectable, ER-positive and/or PR-positive and HER2-negative locally-recurrent or metastatic breast cancer (mBC).

Phase 2

MedSIR